{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "RXO",
  "name": "RXO, Inc.",
  "url": "https://orbyd.app/dossiers/RXO/",
  "json_url": "https://orbyd.app/dossiers/RXO.json",
  "status": "HELD",
  "current_conviction": "MEDIUM",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to consensus; the ~2026-08-05 Q2 print (adj EBITDA guide $27–37M vs $6M Q1) is the binary the whole re-rate discounts.",
  "invalidation_trigger": "A weekly close below $24 loses the May–June breakout shelf and consolidation base; secondary breaks are Q2 adjusted EBITDA (~2026-08-05) printing below the $27–37M guide floor, or the RXO Curve spot index rolling over.",
  "catalyst_date": "2026-08-11",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-28",
  "invalidation_fired": true,
  "themes": [
    "freight-logistics",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Asset-light broker with low gross margin levered to the truckload spot cycle; earnings power tracks the cycle rather than compounding through it.",
    "Beta near 1.9 — sector and index moves land amplified both ways; the February 2026 session in which RXO fell 20.45% on a structural-margin scare is the reference point.",
    "An up-cycle consumes working capital at this business model; check the latest quarter's cash and leverage before assuming the balance sheet absorbs a shock.",
    "Casualty insurance spend of roughly $15–20M a year with a $5M per-occurrence deductible is the only RXO figure publicly quantified against post-Montgomery broker liability.",
    "RXO is not a party to Lipe v. Lupus Superior but trades against its outcome; the broker cohort is discounted on a verdict that is not yet a final judgment."
  ],
  "body_markdown": "## Current Thesis\n\nThe binary resolved and the equity did not re-rate. RXO reported Q2 2026 before the open on 2026-08-06: revenue $1.774B against $1.603B consensus, adjusted EPS $0.06 against $0.03, and adjusted EBITDA of $40M — above the top of the $27–37M guide the prior note called the whole argument. The next day they took back $21.70, +7.21% on 2,004,690 shares, on a single upgrade.\n\nWhat the market re-priced on the beat was the balance sheet. At 2026-06-30 total debt was $506M against $15M of cash, net debt $491M, LTM gross leverage 4.2x and net leverage 4.1x bank-adjusted EBITDA, with $350M of available liquidity and a $200M ABL accordion. Adjusted free cash flow was negative $42M, driven by $70M of working-capital usage as freight rates rose and carrier QuickPay utilisation increased. That is the mechanism of an asset-light broker in an up-cycle: the cycle consumes cash before it produces earnings.\n\nThe sell-side response on 2026-08-07 was four target cuts and one upgrade. TD Cowen kept Sell and went to $17.50 from $19; UBS held Neutral at $23; Citigroup held Neutral at $23, down from the $30 it set on 2026-07-09; Truist held Buy but cut to $28 from the $30 it raised to on 2026-07-15; Citizens upgraded to Market Outperform with a $30 target. A quarter that beat its own guide produced a lower average target.\n\nThe prior note's structural level is gone. The $24 weekly shelf flagged there gave way in the week ended 2026-07-31, which closed $20.25. The name has since traded a $20.24–$22.13 closing band. The frame that matters now is whether a base holds above the print-day low while the cycle data keeps running hot and the liability question stays unquantified beyond one disclosure.\n\n## Bull Case\n\n- **Q2 adjusted EBITDA $40M beat the $27–37M guide and exceeded the $38M earned in Q2 2025** — the first year-over-year EBITDA growth of this cycle, on revenue of $1.774B versus $1.42B a year earlier (Q2 2026 release, 2026-08-06).\n- **Truckload gross profit per load rose 11% sequentially, the fastest in four years**, with spot mix up roughly 900bps sequentially to 42% and pricing growth at a five-year high (Q2 2026 presentation, 2026-08-06). This is the operating-leverage mechanism the cyclical case required, showing up as a measured number rather than a projection.\n- **Truckload volume grew 2% YoY**, which management framed as profitable share gain achieved ahead of schedule (Q2 2026 call, 2026-08-06).\n- **The Q3 2026 guide is adjusted EBITDA $35–45M**, with brokerage volume growth guided to low-to-mid single digits YoY and truckload gross profit per load up sequentially again (2026-08-06).\n- **The spot backdrop remains far above trend.** DAT's dry van report published in early August 2026 put spot linehaul at $2.32/mile, +42.1% YoY and 30.0% above the nine-year seasonal average of $1.78, with the load-to-truck ratio at 10.93 versus 9.92 the prior week and 6.64 a year earlier. Truck posts fell 12.5% week over week and 27.8% YoY — capacity leaving faster than freight.\n- **Insurance exposure got its first public number.** CFO Jamie Harris put annual casualty insurance spend at approximately $15–20M with a $5M deductible per occurrence, and said RXO expects renewal increases meaningfully better than the industry given its claims history and vetting standards (Q2 2026 call, 2026-08-06). Until that call, no RXO figure existed against the post-*Montgomery* liability question.\n\n## Bear Case\n\n- **Leverage moved the wrong way through the beat.** Net leverage 4.1x bank-adjusted at 2026-06-30 against 3.7x reported for Q1 2026, cash down to $15M from $21M, liquidity $350M versus $386M. Management expects the ratio to decline by year-end as EBITDA scales; that is guidance, not a result.\n- **Gross margin keeps compressing.** Q2 2026 gross margin was $247M, 13.9% of revenue, against $252M and 17.8% in Q2 2025 — a lower dollar figure on 25% more revenue. Q1 2026 was 14.2% versus 16.0% a year earlier. Whether this is spot-cycle timing or shipper-side structural pressure is the argument the February 2026 session, in which RXO fell 20.45%, priced violently in one direction.\n- **Negative $42M adjusted free cash flow in the quarter**, on $70M of working-capital usage. A faster recovery consumes more working capital, so the bull case and the cash-burn case share a driver.\n- **Targets fell on a beat.** The 2026-08-07 cluster left the published range roughly $17.50 (TD Cowen) to $35 (BMO, initiated 2026-07-14) — dispersion that measures an unresolved argument rather than a settled view.\n- **The legal benchmark is still uncertified.** The $604M Dallas County verdict in *Lipe v. Lupus Superior* (2026-07-23/24) reached C.H. Robinson through a borrowed-employee vicarious-liability finding, running past its 23% apportioned share; C.H. Robinson has said it will appeal. RXO is not a party, and is being discounted against it anyway.\n- **Spot momentum is easing at the margin.** Dry van linehaul fell 2.4% week over week to $2.32 in the early-August DAT print, after a 2.5% weekly decline to $2.38 in the week ended 2026-07-24.\n\n## Setup & Price Structure\n\nClosing tape into 2026-08-07: $22.64 on 07-28 (-6.10%, TD Cowen downgrade to Sell), $22.29 on 07-29, $20.57 on 07-30 (-7.72% on 3,605,380 shares), $20.25 on 07-31, $20.74 on 08-03, $22.13 on 08-04 (+6.70%), $21.00 on 08-05 (-5.11%), $20.24 on 08-06 (print day, -3.62%), $21.70 on 08-07 (+7.21%). Market cap $3.58B. The 52-week range is $10.43–$29.90, with the high set 2026-07-21.\n\nStructurally: the May–June breakout shelf broke on the weekly close of 2026-07-31. What exists now is nine sessions of chop between a $20.24 closing floor and a $22.64 ceiling, with the print absorbed inside it. There is no reclaim of the pre-downgrade level and no lower low since 08-06. Six of the last ten sessions moved more than 3%, three of them more than 6% — realised volatility consistent with the roughly 1.9 beta the name has carried.\n\n**Narrative life-cycle: SATURATED.** Dating it: 21 analysts cover the name per S&P Global (as of 2026-07-28); the entire sell-side catch-up landed in eight sessions between 2026-07-09 and 2026-07-16; the 52-week high printed 2026-07-21; the first downgrade came 2026-07-28; and five separate houses acted on one day, 2026-08-07, four of them cutting, on a quarter that beat its guide. Coverage arrived at the top, the bid did not follow, and a genuine upside surprise bought one session of gain. That is a well-known story with a thin marginal buyer. The share count barely moved while days-to-cover jumped, meaning average volume thinned. The 2026-08-06 close sat below the declining 20-day, with the July 21 high roughly a third above the print-day close. Retail-facing coverage clustered on the beat headline (Benzinga pre-market movers list, 2026-08-06) on the same day the stock closed red. The earnings date is now behind rather than ahead, which removes the single event that had been suppressing new positioning; no insider-sale or issuance datapoint has been disclosed since the print.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-10 (est.)** — weekly DAT dry van report for the following week. Tests whether the $2.32/mile print extends a second consecutive weekly decline or stabilises with the load-to-truck ratio above 10.\n- **2026-08-11** — Chief Strategy Officer Jared Weisfeld presents at the Deutsche Bank Chicago Industrials Summit, 5:00 p.m. EDT, webcast (announced 2026-08-03). First forum after the print for anything management did not quantify on the call.\n- **~2026-08-11 (est.)** — FINRA short-interest data for the 2026-07-31 settlement. Reads whether the 9.05%-of-float short base was added to or covered through the pre-print drawdown.\n- **2026-08-14** — Q2 2026 13F deadline.\n- **~2026-08-19 (est.)** — RXO Curve Q2 2026 truckload spot-rate report. The Q1 edition (published 2026-05-20) showed index 129, +16.5% YoY, and guided to a larger Q2 growth rate.\n- **~2026-08 to 2026-09 (est.)** — post-trial proceedings in *Lipe v. Lupus Superior*, Dallas County. Whether the court enters, reduces or vacates the ~$604M verdict sets the benchmark the broker cohort is discounted against.\n\n## What Would Change Our Mind\n\nThe structure already broke once: the $24 weekly shelf named in the prior note failed on the 2026-07-31 close of $20.25, and the beat did not repair it. The question is now whether the $20.24 print-day floor holds. **A weekly close below $20 removes the post-print base and leaves no reference level between there and the $10.43 low of the past year.**\n\nOn fundamentals, the case breaks if Q3 adjusted EBITDA lands below the $35–45M guided range, or if the Q3 balance sheet shows net leverage above the 4.1x reported for 2026-06-30 with adjusted free cash flow negative for a second straight quarter — that would establish the up-cycle as cash-consumptive rather than deleveraging. On the cycle, DAT dry van spot extending consecutive weekly declines from $2.32/mile toward the $1.78 nine-year seasonal average, or an RXO Curve Q2 reading below the Q1 +16.5% YoY, removes the offset to the liability discount.\n\nThe upside case would be re-established by a weekly close above $22.64 (the 2026-07-28 pre-downgrade level) with Q3 gross margin rising sequentially from 13.9% — the combination that would separate cyclical margin timing from structural compression. A quantified insurance renewal at or near the existing $15–20M annual casualty spend, disclosed at the 2026-08-11 conference or the Q3 print, would do the same for the legal overhang.\n\n## Correlation Notes\n\n- **C.H. Robinson is the read-through vehicle for legal risk, not for operations.** RXO fell 6.10% on 2026-07-28, the session TD Cowen downgraded it citing a likely wave of broker lawsuits inflating insurance premiums, five days after the Dallas verdict against a company RXO has no interest in. Any post-trial ruling in *Lipe* moves the cohort together.\n- **DAT weekly dry van data and the RXO Curve index drive the cyclical leg**, and they can diverge from the equity: spot ran +45.6% YoY in the week to 2026-07-24 while the stock fell through its base in the same window.\n- **High beta near 1.9 amplifies index and industrials moves in both directions.** The reference session is February 2026, when RXO fell 20.45% on a structural-margin scare, and the 07-30 and 08-05 sessions (-7.72%, -5.11%) show the same character on smaller catalysts.\n- **The truckload-brokerage complex — CHRW, LSTR, JBHT's ICS unit, plus RXO — shares the post-*Montgomery* liability discount**, so a cohort-wide re-rating can move RXO without any RXO-specific news.\n- the mix with the most spot leverage and the most litigation exposure, which is why the cyclical and legal legs of this name are not independent.",
  "first_seen": "2026-04-20",
  "last_analyzed": "2026-08-09T09:38:43+00:00",
  "last_synthesized": "2026-08-09",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}